A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and imdevimab) resulted in the clearance of the infection. Targeted antiviral antibodies may be an important weapon in the management of immunocompromised patients infected with severe acute respiratory syndrome coronavirus 2 who fail to mount an immune response.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344477 | PMC |
| http://dx.doi.org/10.1093/ofid/ofab335 | DOI Listing |
Publication Analysis
Top Keywords
persistent coronavirus
8
coronavirus disease
8
disease 2019
8
successful treatment
4
treatment persistent
4
2019 infection
4
infection patient
4
patient hypogammaglobulinemia
4
hypogammaglobulinemia regn-cov2
4
regn-cov2 case
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!